Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Bristol Myers Squibb announced topline results from the phase I/II open-label TRANSCEND CLL 004, evaluating lisocabtagene maraleucel in adults with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Early data from the single-arm multicenter trial showed that the primary endpoint of complete response rate was met for the prespecified subset of patients pretreated with a BCL-2 inhibitor and who have R/R CLL that was refractory to a BTK inhibitor. TRANSCEND CLL 004 data will be presented at any upcoming medical meeting.